Review



pfripr5 nucleotide sequence  (GenScript corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GenScript corporation pfripr5 nucleotide sequence
    Production of <t>PfRipr5</t> at 2 L stirred-tank bioreactor (STB) scale. (A) Relative PfRipr5 concentration at the TOH of each cell line. (B) SDS-PAGE of purified PfRipr5. (C) Size distribution profile of purified PfRipr5 assessed by dynamic light scattering. (D) ELISA of purified PfRipr5 using an anti- P. falciparum PfRipr mouse monoclonal antibody (mAb) 29B11. For figure (A) : relative PfRipr5 expression was assessed by a densitometry analysis of western blot as described in the M&M section. For figure (B) : L denotes pre-stained protein standard SeeBlue® Plus2, R denotes reduced sample, NR denotes non-reduced sample. Data are relative to one biological replicate ( n = 1).
    Pfripr5 Nucleotide Sequence, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pfripr5 nucleotide sequence/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    pfripr5 nucleotide sequence - by Bioz Stars, 2026-06
    90/100 stars

    Images

    1) Product Images from "Asexual Blood-Stage Malaria Vaccine Candidate PfRipr5: Enhanced Production in Insect Cells"

    Article Title: Asexual Blood-Stage Malaria Vaccine Candidate PfRipr5: Enhanced Production in Insect Cells

    Journal: Frontiers in Bioengineering and Biotechnology

    doi: 10.3389/fbioe.2022.908509

    Production of PfRipr5 at 2 L stirred-tank bioreactor (STB) scale. (A) Relative PfRipr5 concentration at the TOH of each cell line. (B) SDS-PAGE of purified PfRipr5. (C) Size distribution profile of purified PfRipr5 assessed by dynamic light scattering. (D) ELISA of purified PfRipr5 using an anti- P. falciparum PfRipr mouse monoclonal antibody (mAb) 29B11. For figure (A) : relative PfRipr5 expression was assessed by a densitometry analysis of western blot as described in the M&M section. For figure (B) : L denotes pre-stained protein standard SeeBlue® Plus2, R denotes reduced sample, NR denotes non-reduced sample. Data are relative to one biological replicate ( n = 1).
    Figure Legend Snippet: Production of PfRipr5 at 2 L stirred-tank bioreactor (STB) scale. (A) Relative PfRipr5 concentration at the TOH of each cell line. (B) SDS-PAGE of purified PfRipr5. (C) Size distribution profile of purified PfRipr5 assessed by dynamic light scattering. (D) ELISA of purified PfRipr5 using an anti- P. falciparum PfRipr mouse monoclonal antibody (mAb) 29B11. For figure (A) : relative PfRipr5 expression was assessed by a densitometry analysis of western blot as described in the M&M section. For figure (B) : L denotes pre-stained protein standard SeeBlue® Plus2, R denotes reduced sample, NR denotes non-reduced sample. Data are relative to one biological replicate ( n = 1).

    Techniques Used: Concentration Assay, SDS Page, Purification, Enzyme-linked Immunosorbent Assay, Expressing, Western Blot, Staining

    Optimization of PfRipr5 production using insect cells. (A) Optimization strategies devised. (B) Relative PfRipr5 concentration at the TOH between each optimization condition and the baseline production setup (infection with rBAC gp67 without culture temperature shift). A denotes alanine, G denotes glycine, and S denotes serine. Infections were performed using CCI = 2 × 10 6 cell/mL and MOI = 0.1 pfu/cell. Data are expressed as mean ± standard deviation and is relative to three biological replicates ( n = 3).
    Figure Legend Snippet: Optimization of PfRipr5 production using insect cells. (A) Optimization strategies devised. (B) Relative PfRipr5 concentration at the TOH between each optimization condition and the baseline production setup (infection with rBAC gp67 without culture temperature shift). A denotes alanine, G denotes glycine, and S denotes serine. Infections were performed using CCI = 2 × 10 6 cell/mL and MOI = 0.1 pfu/cell. Data are expressed as mean ± standard deviation and is relative to three biological replicates ( n = 3).

    Techniques Used: Concentration Assay, Infection, Standard Deviation

    Production of the PfRipr5 recombinant protein. (A) Kinetics of cell growth and viability upon infection of insect High Five (green) and Sf 9 (orange) cells at different combinations of cell concentration at infection (CCI) and multiplicity of infection (MOI). (B) Kinetics of cell growth and viability upon transfection of human HEK293 cells at different combinations of the PfRipr5 plasSmid DNA (pDNA) concentration (pDNA) and ratio pDNA:PEI. (C) Relative PfRipr5 concentration at the time-of-harvest (TOH) of each production condition. Data are expressed as mean ± standard deviation. For insect cells, data are relative to three biological replicates ( n = 3). For human cells, data are relative to one biological replicate ( n = 1). For figure (A,B) , VCC denotes viable cell concentration. For figure (C) , relative PfRipr5 expression was assessed by a densitometry analysis of western blot as described in the M&M section; graph is normalized at 1 for the best condition using human cells [i.e., (pDNA) = 0.5 mg/L and ratio pDNA:PEI = 1:2 (w:w)].
    Figure Legend Snippet: Production of the PfRipr5 recombinant protein. (A) Kinetics of cell growth and viability upon infection of insect High Five (green) and Sf 9 (orange) cells at different combinations of cell concentration at infection (CCI) and multiplicity of infection (MOI). (B) Kinetics of cell growth and viability upon transfection of human HEK293 cells at different combinations of the PfRipr5 plasSmid DNA (pDNA) concentration (pDNA) and ratio pDNA:PEI. (C) Relative PfRipr5 concentration at the time-of-harvest (TOH) of each production condition. Data are expressed as mean ± standard deviation. For insect cells, data are relative to three biological replicates ( n = 3). For human cells, data are relative to one biological replicate ( n = 1). For figure (A,B) , VCC denotes viable cell concentration. For figure (C) , relative PfRipr5 expression was assessed by a densitometry analysis of western blot as described in the M&M section; graph is normalized at 1 for the best condition using human cells [i.e., (pDNA) = 0.5 mg/L and ratio pDNA:PEI = 1:2 (w:w)].

    Techniques Used: Recombinant, Infection, Concentration Assay, Transfection, Standard Deviation, Expressing, Western Blot

    Production of PfRipr5 at 2 L STB scale using the optimized production strategy (infection of insect High Five cells with rBAC A-GGSGG and culture temperature shift from 27 to 22°C at TOI). (A) Kinetics of cell growth and viability throughout infection. (B) Western blot identification of PfRipr5 in bulk and purified samples. (C) Production yield following purification. (D) SDS-PAGE of purified PfRipr5. (E) Size distribution profile of purified PfRipr5 assessed by dynamic light scattering. (F) ELISA of purified PfRipr5 using an anti- P. falciparum PfRipr mouse mAb 29B11. For figure (A) , VCC denotes viable cell concentration. For figure (B) , DPI denotes day post-infection, (+) denotes the positive control (PfRipr5 produced by WGCFS). For figure (B) and figure (D) , L denotes pre-stained protein standard SeeBlue® Plus2, R denotes reduced sample, and NR denotes non-reduced sample. Infection was performed using CCI = 2 × 10 6 cell/mL and MOI = 0.1 pfu/cell. Data are relative to one biological replicate ( n = 1).
    Figure Legend Snippet: Production of PfRipr5 at 2 L STB scale using the optimized production strategy (infection of insect High Five cells with rBAC A-GGSGG and culture temperature shift from 27 to 22°C at TOI). (A) Kinetics of cell growth and viability throughout infection. (B) Western blot identification of PfRipr5 in bulk and purified samples. (C) Production yield following purification. (D) SDS-PAGE of purified PfRipr5. (E) Size distribution profile of purified PfRipr5 assessed by dynamic light scattering. (F) ELISA of purified PfRipr5 using an anti- P. falciparum PfRipr mouse mAb 29B11. For figure (A) , VCC denotes viable cell concentration. For figure (B) , DPI denotes day post-infection, (+) denotes the positive control (PfRipr5 produced by WGCFS). For figure (B) and figure (D) , L denotes pre-stained protein standard SeeBlue® Plus2, R denotes reduced sample, and NR denotes non-reduced sample. Infection was performed using CCI = 2 × 10 6 cell/mL and MOI = 0.1 pfu/cell. Data are relative to one biological replicate ( n = 1).

    Techniques Used: Infection, Western Blot, Purification, SDS Page, Enzyme-linked Immunosorbent Assay, Concentration Assay, Positive Control, Produced, Staining



    Similar Products

    pfripr5 nucleotide sequence  (GenScript corporation)
    90
    GenScript corporation pfripr5 nucleotide sequence
    Production of <t>PfRipr5</t> at 2 L stirred-tank bioreactor (STB) scale. (A) Relative PfRipr5 concentration at the TOH of each cell line. (B) SDS-PAGE of purified PfRipr5. (C) Size distribution profile of purified PfRipr5 assessed by dynamic light scattering. (D) ELISA of purified PfRipr5 using an anti- P. falciparum PfRipr mouse monoclonal antibody (mAb) 29B11. For figure (A) : relative PfRipr5 expression was assessed by a densitometry analysis of western blot as described in the M&M section. For figure (B) : L denotes pre-stained protein standard SeeBlue® Plus2, R denotes reduced sample, NR denotes non-reduced sample. Data are relative to one biological replicate ( n = 1).
    Pfripr5 Nucleotide Sequence, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pfripr5 nucleotide sequence/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    pfripr5 nucleotide sequence - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Production of PfRipr5 at 2 L stirred-tank bioreactor (STB) scale. (A) Relative PfRipr5 concentration at the TOH of each cell line. (B) SDS-PAGE of purified PfRipr5. (C) Size distribution profile of purified PfRipr5 assessed by dynamic light scattering. (D) ELISA of purified PfRipr5 using an anti- P. falciparum PfRipr mouse monoclonal antibody (mAb) 29B11. For figure (A) : relative PfRipr5 expression was assessed by a densitometry analysis of western blot as described in the M&M section. For figure (B) : L denotes pre-stained protein standard SeeBlue® Plus2, R denotes reduced sample, NR denotes non-reduced sample. Data are relative to one biological replicate ( n = 1).

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: Asexual Blood-Stage Malaria Vaccine Candidate PfRipr5: Enhanced Production in Insect Cells

    doi: 10.3389/fbioe.2022.908509

    Figure Lengend Snippet: Production of PfRipr5 at 2 L stirred-tank bioreactor (STB) scale. (A) Relative PfRipr5 concentration at the TOH of each cell line. (B) SDS-PAGE of purified PfRipr5. (C) Size distribution profile of purified PfRipr5 assessed by dynamic light scattering. (D) ELISA of purified PfRipr5 using an anti- P. falciparum PfRipr mouse monoclonal antibody (mAb) 29B11. For figure (A) : relative PfRipr5 expression was assessed by a densitometry analysis of western blot as described in the M&M section. For figure (B) : L denotes pre-stained protein standard SeeBlue® Plus2, R denotes reduced sample, NR denotes non-reduced sample. Data are relative to one biological replicate ( n = 1).

    Article Snippet: PfRipr5 nucleotide sequence ( ) was codon-optimized for expression in insect or human cells, with an N-terminal gp67 SP sequence to allow secretion into the culture medium, a C-terminal His 6 -tag to allow purification, and a Kozak consensus sequence (GCCACT or ACC for human or insect expression plasmid, respectively) as the translation initiation site (synthetized by GenScript, Leiden, the Netherlands).

    Techniques: Concentration Assay, SDS Page, Purification, Enzyme-linked Immunosorbent Assay, Expressing, Western Blot, Staining

    Optimization of PfRipr5 production using insect cells. (A) Optimization strategies devised. (B) Relative PfRipr5 concentration at the TOH between each optimization condition and the baseline production setup (infection with rBAC gp67 without culture temperature shift). A denotes alanine, G denotes glycine, and S denotes serine. Infections were performed using CCI = 2 × 10 6 cell/mL and MOI = 0.1 pfu/cell. Data are expressed as mean ± standard deviation and is relative to three biological replicates ( n = 3).

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: Asexual Blood-Stage Malaria Vaccine Candidate PfRipr5: Enhanced Production in Insect Cells

    doi: 10.3389/fbioe.2022.908509

    Figure Lengend Snippet: Optimization of PfRipr5 production using insect cells. (A) Optimization strategies devised. (B) Relative PfRipr5 concentration at the TOH between each optimization condition and the baseline production setup (infection with rBAC gp67 without culture temperature shift). A denotes alanine, G denotes glycine, and S denotes serine. Infections were performed using CCI = 2 × 10 6 cell/mL and MOI = 0.1 pfu/cell. Data are expressed as mean ± standard deviation and is relative to three biological replicates ( n = 3).

    Article Snippet: PfRipr5 nucleotide sequence ( ) was codon-optimized for expression in insect or human cells, with an N-terminal gp67 SP sequence to allow secretion into the culture medium, a C-terminal His 6 -tag to allow purification, and a Kozak consensus sequence (GCCACT or ACC for human or insect expression plasmid, respectively) as the translation initiation site (synthetized by GenScript, Leiden, the Netherlands).

    Techniques: Concentration Assay, Infection, Standard Deviation

    Production of the PfRipr5 recombinant protein. (A) Kinetics of cell growth and viability upon infection of insect High Five (green) and Sf 9 (orange) cells at different combinations of cell concentration at infection (CCI) and multiplicity of infection (MOI). (B) Kinetics of cell growth and viability upon transfection of human HEK293 cells at different combinations of the PfRipr5 plasSmid DNA (pDNA) concentration (pDNA) and ratio pDNA:PEI. (C) Relative PfRipr5 concentration at the time-of-harvest (TOH) of each production condition. Data are expressed as mean ± standard deviation. For insect cells, data are relative to three biological replicates ( n = 3). For human cells, data are relative to one biological replicate ( n = 1). For figure (A,B) , VCC denotes viable cell concentration. For figure (C) , relative PfRipr5 expression was assessed by a densitometry analysis of western blot as described in the M&M section; graph is normalized at 1 for the best condition using human cells [i.e., (pDNA) = 0.5 mg/L and ratio pDNA:PEI = 1:2 (w:w)].

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: Asexual Blood-Stage Malaria Vaccine Candidate PfRipr5: Enhanced Production in Insect Cells

    doi: 10.3389/fbioe.2022.908509

    Figure Lengend Snippet: Production of the PfRipr5 recombinant protein. (A) Kinetics of cell growth and viability upon infection of insect High Five (green) and Sf 9 (orange) cells at different combinations of cell concentration at infection (CCI) and multiplicity of infection (MOI). (B) Kinetics of cell growth and viability upon transfection of human HEK293 cells at different combinations of the PfRipr5 plasSmid DNA (pDNA) concentration (pDNA) and ratio pDNA:PEI. (C) Relative PfRipr5 concentration at the time-of-harvest (TOH) of each production condition. Data are expressed as mean ± standard deviation. For insect cells, data are relative to three biological replicates ( n = 3). For human cells, data are relative to one biological replicate ( n = 1). For figure (A,B) , VCC denotes viable cell concentration. For figure (C) , relative PfRipr5 expression was assessed by a densitometry analysis of western blot as described in the M&M section; graph is normalized at 1 for the best condition using human cells [i.e., (pDNA) = 0.5 mg/L and ratio pDNA:PEI = 1:2 (w:w)].

    Article Snippet: PfRipr5 nucleotide sequence ( ) was codon-optimized for expression in insect or human cells, with an N-terminal gp67 SP sequence to allow secretion into the culture medium, a C-terminal His 6 -tag to allow purification, and a Kozak consensus sequence (GCCACT or ACC for human or insect expression plasmid, respectively) as the translation initiation site (synthetized by GenScript, Leiden, the Netherlands).

    Techniques: Recombinant, Infection, Concentration Assay, Transfection, Standard Deviation, Expressing, Western Blot

    Production of PfRipr5 at 2 L STB scale using the optimized production strategy (infection of insect High Five cells with rBAC A-GGSGG and culture temperature shift from 27 to 22°C at TOI). (A) Kinetics of cell growth and viability throughout infection. (B) Western blot identification of PfRipr5 in bulk and purified samples. (C) Production yield following purification. (D) SDS-PAGE of purified PfRipr5. (E) Size distribution profile of purified PfRipr5 assessed by dynamic light scattering. (F) ELISA of purified PfRipr5 using an anti- P. falciparum PfRipr mouse mAb 29B11. For figure (A) , VCC denotes viable cell concentration. For figure (B) , DPI denotes day post-infection, (+) denotes the positive control (PfRipr5 produced by WGCFS). For figure (B) and figure (D) , L denotes pre-stained protein standard SeeBlue® Plus2, R denotes reduced sample, and NR denotes non-reduced sample. Infection was performed using CCI = 2 × 10 6 cell/mL and MOI = 0.1 pfu/cell. Data are relative to one biological replicate ( n = 1).

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: Asexual Blood-Stage Malaria Vaccine Candidate PfRipr5: Enhanced Production in Insect Cells

    doi: 10.3389/fbioe.2022.908509

    Figure Lengend Snippet: Production of PfRipr5 at 2 L STB scale using the optimized production strategy (infection of insect High Five cells with rBAC A-GGSGG and culture temperature shift from 27 to 22°C at TOI). (A) Kinetics of cell growth and viability throughout infection. (B) Western blot identification of PfRipr5 in bulk and purified samples. (C) Production yield following purification. (D) SDS-PAGE of purified PfRipr5. (E) Size distribution profile of purified PfRipr5 assessed by dynamic light scattering. (F) ELISA of purified PfRipr5 using an anti- P. falciparum PfRipr mouse mAb 29B11. For figure (A) , VCC denotes viable cell concentration. For figure (B) , DPI denotes day post-infection, (+) denotes the positive control (PfRipr5 produced by WGCFS). For figure (B) and figure (D) , L denotes pre-stained protein standard SeeBlue® Plus2, R denotes reduced sample, and NR denotes non-reduced sample. Infection was performed using CCI = 2 × 10 6 cell/mL and MOI = 0.1 pfu/cell. Data are relative to one biological replicate ( n = 1).

    Article Snippet: PfRipr5 nucleotide sequence ( ) was codon-optimized for expression in insect or human cells, with an N-terminal gp67 SP sequence to allow secretion into the culture medium, a C-terminal His 6 -tag to allow purification, and a Kozak consensus sequence (GCCACT or ACC for human or insect expression plasmid, respectively) as the translation initiation site (synthetized by GenScript, Leiden, the Netherlands).

    Techniques: Infection, Western Blot, Purification, SDS Page, Enzyme-linked Immunosorbent Assay, Concentration Assay, Positive Control, Produced, Staining